Physician-Industry Interactions on Anti –Vascular Endothelial Growth Factor Use
In this issue ofJAMA Ophthalmology, Taylor et al have used the Centers for Medicare& Medicaid Services (CMS) Open Payments program 2013 database, which provides mandatory reporting data from companies on payments they make to physicians, and the CMS 2013 Provider Utilization and Payment Data: Physician and Other Supplier Public Use File in an innovative manner to assess the putative effect on drug use of payments from Genentech and Regeneron Pharmaceuticals to physicians targeted to those companies ’ specific anti–vascular endothelial growth factor (VEGF) drugs. Specifically, the authors compared physicians...
Source: JAMA Ophthalmology - August 1, 2016 Category: Opthalmology Source Type: research

Error in Figure Key
This article was corrected online. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - August 1, 2016 Category: Opthalmology Source Type: research

Ozurdex in age-related macular degeneration as adjunct to ranibizumab (The OARA Study).
CONCLUSIONS: For this nAMD population, no visual or anatomical benefits were observed when treating with DXI in adjunct to ranibizumab relative to ranibizumab monotherapy. DXI-related adverse events were consistent with those previously documented for dexamethasone. PMID: 27521672 [PubMed - in process] (Source: Canadian Journal of Ophthalmology)
Source: Canadian Journal of Ophthalmology - August 1, 2016 Category: Opthalmology Authors: Chaudhary V, Barbosa J, Lam WC, Mak M, Mavrikakis E, Mohaghegh P SM Tags: Can J Ophthalmol Source Type: research

Neovascular age ‐related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections
Abstract PurposeTo study visual outcome and number of annual injections in treatment‐naïve patients with neovascular age‐related macular degeneration (nAMD) before and after a change in first‐line therapy from ranibizumab to aflibercept in a high‐volume clinical practice. MethodsThis was a retrospective chart review of routine clinical practice. The study included 1027 treatment‐naïve patients, 559 of whom started intravitreal ranibizumab therapy in 2011–2012 and 468 of whom started intravitreal aflibercept therapy in 2013–2014, a fixed loading dose of three injections followed by a pro re n...
Source: Acta Ophthalmologica - August 1, 2016 Category: Opthalmology Authors: Annette Rasmussen, Birgit Sander, Michael Larsen, Sara Brandi, Josefine Fuchs, Louise H. Hansen, Henrik Lund ‐Andersen Tags: Original Article Source Type: research

Ranibizumab for the Prevention of Radiation Complications in Patients Treated With Proton Beam Irradiation for Choroidal Melanoma.
Abstract PURPOSE: To investigate the safety and potential efficacy of ranibizumab for prevention of radiation complications in patients treated with proton irradiation for choroidal melanoma. METHODS: Forty patients with tumors located within 2 disc diameters of the optic nerve and/or macula were enrolled in this open-label study. Participants received ranibizumab 0.5 mg or 1.0 mg at tumor localization and every 2 months thereafter for the study duration of 24 months. The incidence of adverse events, visual acuity, and other measures of ocular morbidity related to radiation complications were assessed. Histor...
Source: Transactions of the American Ophthalmological Society - August 1, 2016 Category: Opthalmology Authors: Kim IK, Lane AM, Jain P, Awh C, Gragoudas ES Tags: Trans Am Ophthalmol Soc Source Type: research

Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes
ConclusionIntravitreal ranibizumab can be effective in previously vitrectomized eyes with diabetic macular oedema. However, the response is variable and should be carefully monitored. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - July 30, 2016 Category: Opthalmology Authors: Caroline Schmidt Laugesen, Christoffer Ostri, Troels Brynskov, Henrik Lund ‐Andersen, Michael Larsen, Henrik Vorum, Torben L. Sørensen Tags: Original Article Source Type: research

[Regional Differences in the Care of Patients with Neovascular Age-Related Macular Degeneration, Based on the Non-Interventional OCEAN Study].
Conclusion: No major regional differences were observed in the demographic characteristics of the patient population. The main regional disparities in the care of nAMD patients were in the application of diagnostic methods and the waiting times between the first examination and the first drug administration. The regional variations in treatment delays could clearly influence the risk of worse functional outcome. PMID: 27454304 [PubMed - as supplied by publisher] (Source: Klinische Monatsblatter fur Augenheilkunde)
Source: Klinische Monatsblatter fur Augenheilkunde - July 28, 2016 Category: Opthalmology Tags: Klin Monbl Augenheilkd Source Type: research

[Functional and Morphological Microstructural Changes in SD-OCT in Long-Term Treatment for Neovascular AMD with Ranibizumab - Monotherapy Versus Combination Therapy with PDT].
Conclusion: In a long-term follow-up of 5.3 years, patients with nAMD in both groups exhibited good stabilisation of visual acuity. In both groups, retinal thickness decreased and the base of the subretinal plaque increased. With respect to SD-OCT morphological criteria, patients in group A (monotherapy) responded slightly better to therapy than patients in group B (combination group). PMID: 27454303 [PubMed - as supplied by publisher] (Source: Klinische Monatsblatter fur Augenheilkunde)
Source: Klinische Monatsblatter fur Augenheilkunde - July 28, 2016 Category: Opthalmology Tags: Klin Monbl Augenheilkd Source Type: research

Effect of intravitreal anti-VEGF on choroidal thickness in patients with diabetic macular edema using spectral domain OCT
Conclusions: Over a 6-month period, the use of intravitreal anti-VEGF was associated with significant thinning of the choroid in patients with DME. The clinical significance of a thinner choroid in DME is currently unknown; however, it may contribute to long-term adverse effects on choroidal and retinal function, representing an area requiring future investigation. RESUMO Objetivos: Avaliar a espessura de coroide pr é-tratamento e após 6 meses da injeção intravítrea de anti-fator de crescimento vascular endotelial (anti-VEGF) em pacientes com edema macular diabético (EMD), utilizan...
Source: Arquivos Brasileiros de Oftalmologia - July 26, 2016 Category: Opthalmology Source Type: research

Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration
Conclusion: Intravitreal ranibizumab for nAMD prevents severe visual loss in real-world practice. Patients can achieve visual gain from baseline, but the extent to which these are maintained in the long term may depend on the frequency of injections. (Source: RETINA)
Source: RETINA - July 26, 2016 Category: Opthalmology Tags: Review Source Type: research

Intravitreal ranibizumab for choroidal neovascularization in a patient with angioid streaks and multiple evanescent white dots
To report a patient with angioid streaks (ASs) and coincident multiple evanescent white dot syndrome (MEWDS) who developed choroidal neovascularization (CNV). (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - July 26, 2016 Category: Opthalmology Authors: Alfredo Pece, Davide Allegrini, Stelios Kontadakis, Giuseppe Querques and Luca Rossetti Source Type: research

The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK
Conclusion This evaluation suggests that treating patients with ranibizumab according to the T & amp;E regimen could be a better use of NHS resources than aflibercept, and could, therefore, be considered as a first-line regimen for patients with wet AMD in the UK. Funding Novartis Pharmaceuticals UK Limited. (Source: Advances in Therapy)
Source: Advances in Therapy - July 25, 2016 Category: Drugs & Pharmacology Source Type: research

Baseline Characteristics of the Fellow Eye in Patients with Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the VIEW Studies
Conclusions: In patients in the VIEW studies, most fellow eyes had evidence of AMD, highlighting the importance of examining both eyes, with close follow-up thereafter, in order to detect and treat CNV earlier as needed. Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - July 22, 2016 Category: Opthalmology Source Type: research

Application of the Price –Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy
Abstract Several cases of expensive drugs designed for large patient populations (e.g. sofosbuvir) have raised a complex question in terms of drug pricing. Even assuming value-based pricing, the treatment with these drugs of all eligible patients would have an immense budgetary impact, which is unsustainable also for the richest countries. This raises the need to reduce the prices of these agents in comparison with those suggested by the value-based approach and to devise new pricing methods that can achieve this goal. The present study discusses in detail the following two methods: (i) The approach based on setting natio...
Source: Clinical Drug Investigation - July 22, 2016 Category: Drugs & Pharmacology Source Type: research

Intravitreal ranibizumab for choroidal neovascularization secondary to angiod streaks. Comparison of the 12 and 24-month results of treatment in treatment-naïve eyes.
Intravitreal ranibizumab for choroidal neovascularization secondary to angiod streaks. Comparison of the 12 and 24-month results of treatment in treatment-naïve eyes. Eur Rev Med Pharmacol Sci. 2016 Jul;20(13):2779-85 Authors: Ladas DS, Koutsandrea C, Kotsolis AI, Georgalas I, Moschos MM, Ladas ID Abstract OBJECTIVE: Our aim study was to compare 12 and 24-month results of intravitreal ranibizumab therapy in the management of choroidal neovascularization (CNV) secondary to angioid streaks (ST). This could be of clinical importance helping us planning optimal dosing strategies. PATIENTS AND METH...
Source: European Review for Medical and Pharmacological Sciences - July 21, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision
Background/aims To evaluate baseline low-luminance visual acuity (LLVA) as a predictor of visual acuity improvement in patients with neovascular (wet) age-related macular degeneration (wAMD) receiving antivascular endothelial growth factor A (anti-VEGF) therapy. Methods In the HARBOR trial, 1084 treatment-naïve patients ≥50 years of age with subfoveal wAMD received intravitreal ranibizumab 0.5 or 2.0 mg monthly or as needed. To measure LLVA, patients read a normally illuminated ETDRS (Early Treatment Diabetic Retinopathy Study) chart with a neutral density filter placed in front of the study eye. Patients w...
Source: British Journal of Ophthalmology - July 21, 2016 Category: Opthalmology Authors: Frenkel, R. E. P., Shapiro, H., Stoilov, I. Tags: Retina, Open access Original articles - Clinical science Source Type: research

Incidence and clinical features of post-injection endophthalmitis according to diagnosis
Purpose To compare the incidence and clinical features of endophthalmitis after intravitreal antivascular endothelial growth factor (VEGF) therapy for diabetic eye disease, neovascular age-related macular degeneration (AMD) and retinal vein occlusion (RVO). Methods Multicentre, retrospective, consecutive case–control study. All patients treated with intravitreal bevacizumab, ranibizumab or aflibercept for diabetic eye disease, neovascular AMD or RVO between 1 January 2009 and 30 September 2013 at three retina practices were included in this study. The total number of anti-VEGF injections administered for the three i...
Source: British Journal of Ophthalmology - July 21, 2016 Category: Opthalmology Authors: Rayess, N., Rahimy, E., Shah, C. P., Wolfe, J. D., Chen, E., DeCroos, F. C., Storey, P., Garg, S. J., Hsu, J. Tags: Choroid, Eye (globe), Retina, Epidemiology Original articles - Clinical science Source Type: research

The Efficacy and Safety of Current Treatments in Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis
Conclusions Our analysis confirms that intravitreal aflibercept is most favorable with both BCVA improvement and CMT decrease than other current therapies in the management of DME within 12 months. Vascular endothelial growth factor inhibitors for DME should be used with caution due to systematic AEs. Combined intravitreal triamcinolone with LASER has a stronger efficacy in decreasing CMT than the other interventions in the early stage after injection. More high-quality randomized controlled trials will be necessary. (Source: PLoS One)
Source: PLoS One - July 19, 2016 Category: Biomedical Science Authors: Lu Zhang Source Type: research

Ranibizumab for persistent diabetic macular edema after bevacizumab treatment.
CONCLUSIONS: Switching to ranibizumab resulted in a significant decrease in the CRT of eyes with DME, and should be considered when there is a lack of response or deterioration while on bevacizumab injections. A significant gain in VA was observed in a subgroup of eyes that lost more than one line while receiving the last 3 bevacizumab injections prior to the switch. PMID: 27445070 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - July 18, 2016 Category: Opthalmology Authors: Katz G, Moisseiev E, Goldenberg D, Moisseiev J, Lomnicky Y, Abend Y, Treister G, Levkovitch-Verbin H Tags: Eur J Ophthalmol Source Type: research

Short-term Efficacy of Intravitreal Dexamethasone Implant in Vitrectomized Eyes with Recalcitrant Diabetic Macular Edema and Prior Anti-VEGF Therapy.
CONCLUSION: In vitrectomized eyes previously treated with anti-VEGF agents for recalcitrant DME, implantation of the IDI appears to be efficacious in improving VA and CRT at 1-month with the observed benefits persisting for at least for 3 months. PMID: 27413499 [PubMed] (Source: Journal of Ophthalmic and Vision Research)
Source: Journal of Ophthalmic and Vision Research - July 16, 2016 Category: Opthalmology Tags: J Ophthalmic Vis Res Source Type: research

Macular atrophy in patients with long‐term anti‐VEGF treatment for neovascular age‐related macular degeneration
ConclusionA majority of patients show MA after long‐term anti‐VEGF treatment. Reticular pseudodrusen (RPD), IRC and PVD but not number of injections or treatment duration seem to be associated with the MA size. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - July 15, 2016 Category: Opthalmology Authors: Marion R. Munk, Lala Ceklic, Andreas Ebneter, Wolfgang Huf, Sebastian Wolf, Martin S. Zinkernagel Tags: Original Article Source Type: research

Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Abstract PURPOSE: To evaluate the efficacies and treatment outcomes following intravitreal bevacizumab (IVB), intravitreal ranibizumab (IVR), and laser photocoagulation (LPC) in retinopathy of prematurity (ROP). METHODS: This was a retrospective interventional case series study including the data of 134 infants (264 eyes) who were treated with IVB, IVR, or LPC for ROP. The data were collected from two major ROP treatment centers in Turkey without any randomization or masking. Regression of ROP, recurrence profile, complications after each treatment modality, and indications for retreatment were evaluated. The...
Source: Current Eye Research - July 15, 2016 Category: Opthalmology Authors: Gunay M, Sukgen EA, Celik G, Kocluk Y Tags: Curr Eye Res Source Type: research

Macular atrophy in patients with long ‐term anti‐VEGF treatment for neovascular age‐related macular degeneration
ConclusionA majority of patients show MA after long‐term anti‐VEGF treatment. Reticular pseudodrusen (RPD), IRC and PVD but not number of injections or treatment duration seem to be associated with the MA size. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - July 15, 2016 Category: Opthalmology Authors: Marion R. Munk, Lala Ceklic, Andreas Ebneter, Wolfgang Huf, Sebastian Wolf, Martin S. Zinkernagel Tags: Original Article Source Type: research

Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy
To evaluate costs of panretinal photocoagulation (PRP) vs. intravitreal ranibizumab (IVR) for proliferative diabetic retinopathy (PDR). (Source: Ophthalmology)
Source: Ophthalmology - July 14, 2016 Category: Opthalmology Authors: James Lin, Jonathan S. Chang, William E. Smiddy Source Type: research

Distinct Responsiveness to Intravitreal Ranibizumab Therapy in Polypoidal Choroidal Vasculopathy With Single or Multiple Polyps
We would like to thank Drs Uzun and Pehlivan for their interest in our recent study, which demonstrates the different responses to intravitreal 0.5 mg ranibizumab (IVR) therapy in 2 groups with treatment-naïve polypoidal choroidal vasculopathy (PCV), a subtype of age-related macular degeneration (AMD). The groups were classified according to the presence of single or multiple polyps.1 Although the baseline central retinal thickness (CRT) was almost the same between the groups, and both groups showed reduction in CRT after IVR, the single-polyp group showed significantly thinner CRT compared with the multiple-polyps gr...
Source: American Journal of Ophthalmology - July 14, 2016 Category: Opthalmology Authors: Misa Suzuki, Norihiro Nagai, Hajime Shinoda, Atsuro Uchida, Toshihide Kurihara, Yohei Tomita, Mamoru Kamoshita, Chigusa Iyama, Kazuo Tsubota, Yoko Ozawa Tags: Correspondence Source Type: research

Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic  Retinopathy
To evaluate costs of panretinal photocoagulation (PRP) vs. intravitreal ranibizumab (IVR) for proliferative diabetic retinopathy (PDR). (Source: Ophthalmology)
Source: Ophthalmology - July 14, 2016 Category: Opthalmology Authors: James Lin, Jonathan S. Chang, William E. Smiddy Source Type: research

Distinct Responsiveness to Intravitreal Ranibizumab Therapy in Polypoidal Choroidal Vasculopathy With Single or Multiple Polyps
We would like to thank Drs Uzun and Pehlivan for their interest in our recent study, which demonstrates the different responses to intravitreal 0.5 mg ranibizumab (IVR) therapy in 2 groups with treatment-na ïve polypoidal choroidal vasculopathy (PCV), a subtype of age-related macular degeneration (AMD). The groups were classified according to the presence of single or multiple polyps.1 Although the baseline central retinal thickness (CRT) was almost the same between the groups, and both groups showed reduction in CRT after IVR, the single-polyp group showed significantly thinner CRT compared with the multiple-polyps g...
Source: American Journal of Ophthalmology - July 14, 2016 Category: Opthalmology Authors: Misa Suzuki, Norihiro Nagai, Hajime Shinoda, Atsuro Uchida, Toshihide Kurihara, Yohei Tomita, Mamoru Kamoshita, Chigusa Iyama, Kazuo Tsubota, Yoko Ozawa Tags: Correspondence Source Type: research

Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
Conclusions Time-resolved phosphorescence anisotropy is a relatively simple and straightforward method that allows experimental measurement of the hydrodynamic radius of individual proteins, and is superior to theoretical calculations which cannot give the required accuracy for a particular protein. (Source: Pharmaceutical Research)
Source: Pharmaceutical Research - July 13, 2016 Category: Drugs & Pharmacology Source Type: research

Mycobacterium chelonae Scleral Abscess After Intravitreal Ranibizumab Injection
Conclusions: Injection-site scleral abscesses are very rare and serious complications of intravitreal injections. Once the abscess is drained, it is possible to identify the organism and treat the infection with appropriate combination antibiotic therapy. (Source: Cornea)
Source: Cornea - July 8, 2016 Category: Opthalmology Tags: Case Report Source Type: research

Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study
We appreciate the interest of Drs Călugăru in our recently published COMRADE-C trial1 comparing the clinical efficacy and safety of ranibizumab vs dexamethasone in macular edema secondary to central retinal vein occlusion (CRVO). (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - July 8, 2016 Category: Opthalmology Authors: Hans Hoerauf, Nicolas Feltgen, Claudia Weiss, Eva-Maria Paulus, Steffen Schmitz-Valckenberg, Amelie Pielen, Pankaj Puri, Hüsnü Berk, Nicole Eter, Peter Wiedemann, Gabriele E. Lang, Matus Rehak, Armin Wolf, Thomas Bertelmann, Lars-Olof Hattenbach, COMRAD Tags: Correspondence Source Type: research

Distinct Responsiveness to Intravitreal Ranibizumab Therapy in Polypoidal Choroidal Vasculopathy With Single or Multiple Polyps
We have read the article published in the Journal by Suzuki and associates: “Distinct responsiveness to intravitreal ranibizumab therapy in polypoidal choroidal vasculopathy with single or multiple polyps.”1 In that paper, the prognosis of polypoidal choroidal vasculopathy (PCV) has been investigated by taking the response of the patients to intravitreal ranibizumab (IVR) monotherapy in the presence of a single or multiple polyps. The authors included 48 previously untreated eyes of 48 patients who received monthly IVR injections for 3 months, followed by pro re nata (PRN) injections. (Source: American Jou...
Source: American Journal of Ophthalmology - July 8, 2016 Category: Opthalmology Authors: Salih Uzun, Emre Pehlivan Tags: Correspondence Source Type: research

Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study
We would like to address several challenges arising from the interesting study by Hoerauf and associates,1 which can be specifically summarized as follows: (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - July 8, 2016 Category: Opthalmology Authors: Dan Călugăru, Mihai Călugăru Tags: Correspondence Source Type: research

Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study
We appreciate the interest of Drs C ălugăru in our recently published COMRADE-C trial1 comparing the clinical efficacy and safety of ranibizumab vs dexamethasone in macular edema secondary to central retinal vein occlusion (CRVO). (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - July 8, 2016 Category: Opthalmology Authors: Hans Hoerauf, Nicolas Feltgen, Claudia Weiss, Eva-Maria Paulus, Steffen Schmitz-Valckenberg, Amelie Pielen, Pankaj Puri, H üsnü Berk, Nicole Eter, Peter Wiedemann, Gabriele E. Lang, Matus Rehak, Armin Wolf, Thomas Bertelmann, Lars-Olof Hattenbach, COMRA Tags: Correspondence Source Type: research

Distinct Responsiveness to Intravitreal Ranibizumab Therapy in Polypoidal Choroidal Vasculopathy With Single or Multiple Polyps
We have read the article published in the Journal by Suzuki and associates: “Distinct responsiveness to intravitreal ranibizumab therapy in polypoidal choroidal vasculopathy with single or multiple polyps.”1 In that paper, the prognosis of polypoidal choroidal vasculopathy (PCV) has been investigated by taking the response of the patients to intravitreal ranibizumab (IV R) monotherapy in the presence of a single or multiple polyps. The authors included 48 previously untreated eyes of 48 patients who received monthly IVR injections for 3 months, followed by pro re nata (PRN) injections. (Source: American Jo...
Source: American Journal of Ophthalmology - July 8, 2016 Category: Opthalmology Authors: Salih Uzun, Emre Pehlivan Tags: Correspondence Source Type: research

Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study
We would like to address several challenges arising from the interesting study by Hoerauf and associates,1 which can be specifically summarized as follows: (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - July 8, 2016 Category: Opthalmology Authors: Dan C ălugăru, Mihai Călugăru Tags: Correspondence Source Type: research

Gene Therapy for Age-Related Macular Degeneration
Abstract: The purpose of this article was to evaluate safety and signals of efficacy of gene therapy with subretinal rAAV.sFlt-1 for wet age-related macular degeneration (wet AMD). A phase 1 dose-escalating single-center controlled unmasked human clinical trial was followed up by extension of the protocol to a phase 2A single-center trial. rAAV.sFlt-1 vector was used to deliver a naturally occurring anti–vascular endothelial growth factor agent, sFlt-1, into the subretinal space. In phase 1, step 1 randomized 3 subjects to low-dose rAAV.sFlt-1 (1 × 1010 vector genomes) and 1 subject to the control arm; step 2 r...
Source: Asia-Pacific Journal of Ophthalmology - July 1, 2016 Category: Opthalmology Tags: Review Article Source Type: research

Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response
Conclusion:CFH is implicated in nAMD patient treatment response to ranibizumab.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - June 30, 2016 Category: Opthalmology Source Type: research

Comparison of the Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema in Vitrectomized and Nonvitrectomized Eyes
Purpose: To compare the effectiveness of intravitreal ranibizumab (IVR) for diabetic macular edema (DME) between eyes with and without previous vitrectomy. Procedures: We prospectively assessed the best-corrected visual acuity (BCVA) and central macular thickness (CMT) after IVR for 6 months. Results: There were no significant differences in the baseline BCVA and CMT between both groups. In the nonvitrectomized group (n = 15), the mean changes of BCVA and CMT from baseline to month 6 were significant (p
Source: Ophthalmologica - June 30, 2016 Category: Opthalmology Source Type: research

[Atrophy of the macula in the context of its wet, age-related degeneration : An inescapable consequence of anti-VEGF therapy?]
CONCLUSIONS: Despite doubts regarding the long-term safety of anti-VEGF therapy, it is the author's view that this is the only option to stabilise visual function. The impact of therapy-induced damage on the spontaneous progression of AMD and the biological status of the aging individual cannot be unequivocally assessed. PMID: 27364637 [PubMed - as supplied by publisher] (Source: Der Ophthalmologe)
Source: Der Ophthalmologe - June 30, 2016 Category: Opthalmology Authors: Garweg JG Tags: Ophthalmologe Source Type: research

Visual Acuity of Eyes with Early Persistent Retinal Fluid from Neovascular Age-Related Macular Degeneration in the VIEW Studies
To compare the effect of intravitreal aflibercept or ranibizumab drug type and frequency on visual acuity outcomes in eyes with neovascular age-related macular degeneration (NVAMD) and early persistent retinal fluid after 3 initial monthly injections. (Source: Ophthalmology)
Source: Ophthalmology - June 28, 2016 Category: Opthalmology Authors: Glenn J. Jaffe, Peter K. Kaiser, Desmond Thompson, Andrea Gibson, Namrata Saroj, Robert Vitti, Alyson J. Berliner, Jeffrey S. Heier Source Type: research

Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid
To compare the effect of intravitreal aflibercept or ranibizumab drug type and frequency on visual acuity outcomes in eyes with neovascular age-related macular degeneration (NVAMD) and early persistent retinal fluid after 3 initial monthly injections. (Source: Ophthalmology)
Source: Ophthalmology - June 28, 2016 Category: Opthalmology Authors: Glenn J. Jaffe, Peter K. Kaiser, Desmond Thompson, Andrea Gibson, Namrata Saroj, Robert Vitti, Alyson J. Berliner, Jeffrey S. Heier Source Type: research

Ranibizumab for diabetic macular edema refractory to multiple prior treatments
This study sought to investigate this observation further. Methods: Retrospective chart review. Results: Thirty-three eyes of 22 patients with refractory diabetic macular edema were treated with 0.3 mg intravitreal ranibizumab. This group of eyes received an average of 5.1 prior treatments (macular laser, intravitreal bevacizumab, triamcinolone acetonide, or dexamethasone implant). The mean best corrected visual acuity before the initial ranibizumab injection was 20/110 and the mean central subfield thickness was 384 μm. After 7 visits over an average of 48 weeks, during which an average of 6 ranibizumab injections we...
Source: RETINA - June 24, 2016 Category: Opthalmology Tags: Original Study Source Type: research

RETINAL LAYER RESPONSE TO RANIBIZUMAB DURING TREATMENT OF DIABETIC MACULAR EDEMA: Thinner is Not Always Better
Purpose: To identify individual retinal layer thickness changes associated with visual acuity gain in diabetic macular edema treated with ranibizumab using layer segmentation on high-resolution optical coherence tomography scans. Methods: Retrospective observational case series. Thirty-three treatment-naive eyes with diabetic macular edema were imaged by spectral domain optical coherence tomography at monthly visits while receiving intravitreal ranibizumab treatment as needed, guided by visual acuity. Thickness changes of individual layers after 1 year were quantitatively analyzed and correlated with visual acuity gain. ...
Source: RETINA - June 24, 2016 Category: Opthalmology Tags: Original Study Source Type: research

Implication of recurrent or retained fluid on optical coherence tomography for visual acuity during active treatment of neovascular age-related macular degeneration with a treat and extend protocol
Purpose: Assess the correlation between optical coherence tomography findings and change in vision for patients receiving “treat and extend” protocol ranibizumab for neovascular age-related macular degeneration. Methods: Optical coherence tomography analysis and best-corrected visual acuity (BCVA) change: mild = 5 to 9 letters, moderate = 10 to 14 letters, and severe ≥15 letters. Results: A total of 103 eyes (99 patients, 63% female, 65–91 years) followed for 20.8 ± 4.9 months. By 12 months, there were 1.38 ± 0.59 instances of intraretinal fluid (IRF)/subretinal fluid recurrence on opti...
Source: RETINA - June 24, 2016 Category: Opthalmology Tags: Original Study Source Type: research

PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.6b00335 (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - June 22, 2016 Category: Drugs & Pharmacology Authors: Naba Elsaid, Timothy L. Jackson, Zeeneh Elsaid, Aljawharah Alqathama and Satyanarayana Somavarapu Source Type: research

PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab
Molecular Pharmaceutics DOI: 10.1021/acs.molpharmaceut.6b00335 (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - June 22, 2016 Category: Drugs & Pharmacology Authors: Naba Elsaid, Timothy L. Jackson, Zeeneh Elsaid, Aljawharah Alqathama and Satyanarayana Somavarapu Source Type: research

[French practice patterns in the management of diabetic macular edema].
CONCLUSION: Most of the specialists initiate DME treatment for a VA>0.5 in France. Eighty-five percent of them perform bilateral intravitreal injections on the same day in the case of bilateral DME. PMID: 27318630 [PubMed - as supplied by publisher] (Source: Journal Francais d Ophtalmologie)
Source: Journal Francais d Ophtalmologie - June 21, 2016 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration
Conclusions Though our study suggests superiority of the treat and extend regimen to PRN treatment in a 12-month period, this review demonstrates the need for randomised clinical trials to confirm our findings and to evaluate long-term efficacy outcomes with these regimens compared with monthly therapy. (Source: British Journal of Ophthalmology)
Source: British Journal of Ophthalmology - June 21, 2016 Category: Opthalmology Authors: Chin-Yee, D., Eck, T., Fowler, S., Hardi, A., Apte, R. S. Tags: Retina Original articles - Clinical science Source Type: research

Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
CONCLUSION: This study demonstrates that apoptosis was induced in the retina of newborn rabbits by intravitreal administration of anti-VEGF agents together with reduction in serum VEGF levels. Among the three anti-VEGF agents, ranibizumab caused the least apoptotic activity in the retina and reduction in serum VEGF levels. In light of our study, we believe that intravitreal anti-VEGF agents should be used with caution as a first line treatment for the treatment of retinopathy of prematurity. PMID: 27314606 [PubMed - as supplied by publisher] (Source: Current Eye Research)
Source: Current Eye Research - June 17, 2016 Category: Opthalmology Authors: Cam D, Berk AT, Micili SC, Kume T, Ergur BU, Yilmaz O Tags: Curr Eye Res Source Type: research